ChartMill assigns a Buy % Consensus number of 49% to FSTX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-07-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-06-24 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2021-08-17 | SVB Leerink | Maintains | Outperform |
| 2021-07-08 | SVB Leerink | Initiate | Outperform |
| 2021-06-09 | B. Riley Securities | Initiate | Buy |
| 2021-05-18 | HC Wainwright & Co. | Initiate | Buy |
| 2021-04-16 | Oppenheimer | Initiate | Outperform |
| 2021-04-08 | William Blair | Initiate | Outperform |
| 2021-03-24 | Laidlaw & Co. | Initiate | Buy |
| 2021-03-01 | HC Wainwright & Co. | Initiate | Buy |
9 analysts have analysed FSTX and the average price target is 7.14 USD. This implies a price increase of 0.28% is expected in the next year compared to the current price of 7.12.
The consensus rating for F-STAR THERAPEUTICS INC (FSTX) is 48.8889 / 100 . This indicates that analysts generally have a neutral outlook on the stock.